Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry

Blood

Volumn 104, Issue 12, 2004, Pages 3797-3803

  Freytes, César O ^a   Loberiza, Fausto R ^b   Rizzo, J Douglas ^b   Bashey, Asad ^b   Bredeson, Christopher N ^b   Cairo, Mitchell S ^b   Gale, Robert Peter ^b   Horowitz, Mary M ^b   Klumpp, Thomas R ^b   Martino, Rodrigo ^b   McCarthy, Philip L ^b   Molina, Arturo ^b   Pavlovsky, Santiago ^b   Pecora, Andrew L ^b   Serna, Derek S ^b   Tsai, Tsuong ^b   Zhang, Mei Jie ^b   Vose, Julie M ^b   Lazarus, Hillard M ^b   Van Besien, Koen ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MYELOABLATIVE AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CONTROL; CANCER RECURRENCE; CANCER REGISTRY; CANCER REGRESSION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE; WHOLE BODY RADIATION;

EID: 9444272217     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0231     Document Type: Article

References (33)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Vose JM, Zhang M-J, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry (ABMTR). J Clin Oncol. 2001;19:406-413.
3. Lazarus HM, Loberiza FR Jr, Zhang M-J, et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the Autologous Blood and Marrow Transplant Registry (ABMTR). Bone Marrow Transplant. 2001;27:387-396.
4. Vose JM, Bierman PJ, Anderson JR, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood. 1992;80:2142-2148.
5. Shamash J, Lee SM, Radford JA, et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol. 2000;11:715-719.
6. Petersen FB, Appelbaum FR, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol. 1990;8:638-647.
7. Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Marrow Registry. J Clin Oncol. 1997;15:1595-1600.
8. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19:121-127.
9. Freytes CO, Loberiza FR, Rizzo JD, et al. Allogeneic transplantation in patients that relapsed after autologous transplantation for lymphoma: a report from the International Bone Marrow Transplant Registry [abstract]. J Clin Oncol. 2002;21:414.
10. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
11. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin or relapse after autologous bone marrow transplantation. Lancet. 1993;341:85-86.
12. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20:859-863.
13. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant. 2000;6:272-279.
14. Schouten HC, Armitage JO, Klassen LW, et al. Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation. Bone Marrow Transplant. 1989;4:119-121.
15. Bierman P, Kottaridis P, Kollath J, et al. Allogeneic transplantation following failure of autologous transplantation for lymphoma [abstract]. Blood. 1998;92:321.
16. Shah AJ, Kapoor N, Weinberg KI, et al. Second hematopoietic stem cell transplantation in pediatric patients: overall survival and long-term follow-up. Biol Blood Marrow Transplant. 2002;8:221-228.
17. Chiang KY, Weisdorf DJ, Davies SM, et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant. 1996;17:39-42.
18. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphoma: summary and description of a working formulation for clinical usage: the Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
19. Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32:763-769.
20. van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529.
21. Stiff PJ, Unger JM, Forman SJ, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant. 2003;9:529-539.
22. Stiff PJ, Dahlberg S, Foreman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens-a Southwest Oncology Group Trial. J Clin Oncol. 1998;16:48-55.
23. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92:1832-1836.
24. van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effects. Bone Marrow Transplant. 1997;19:977-982.
25. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
26. Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002;99:75-82.
27. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
28. Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21:3744-3753.
29. van Besien KW, Mehra RC, Giralt SA, et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996;100:299-307.
30. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation and with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
31. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Second allogeneic stem-cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol. 2000;28:1096-1104.
32. Branson K, Chopra R, Kottaridis PD, et al. Role of nonmyeloablative allogeneic stem cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol. 2002;20:4022-4031.
33. Feinstein LC, Sandmaier BM, Maloney DG, et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2003;9:266-272.